Trial document

drksid header


Trial Description

start of 1:1-Block title


Identfication of tumor-specific and tumor-associated antigens for potential clinical application in vaccination studies - Part: Squamous cell cancer of the head and neck

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Cancer develops through uncontrolled growth of cells of a different origin. To this end, many changes of genetic information, cell metabolism and immune interactions have to develop. In this regard, genetic mutations can lead to alterations of cellular metabolism leading to production of proteins which are not occurring in non-malignant tissue. The immune system can regognize such structures and specifically attack tumor cells.
This study aims at the direct identification of these tumor-specific and/or tumor-associated antigens comparing cancer- and non-malignant tissue. In future clinical trials, the identified structured could be used for stimulation of a tumor-specific immune response.

Study participants:
30 patients with confirmed diagnosis of head and neck squamous cell carcinoma and indication for surgical resection.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

During malignant transformation, tumor cells develop multiple alteration in genetic information, cell proliferation, metabolism and adhesion. These alterations result in aberrant expression of HLA-restricted tumor-associated and/or tumor-specific antigens which can be recognized by the immune system. This recognition does not lead to sufficient rejection of established tumors. This study aims to identify immunologically relevant target structures which can be utilized in future clinical vaccine trials.

Study participants:
30 patients with confirmed diagnosis of head and neck squamous cell carcinoma and indication for surgical resection.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00014018
  •   2018/02/14
  •   [---]*
  •   yes
  •   Approved
  •   222/2015BO2, Ethik-Kommission an der Medizinischen Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum Tübingen
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C32 -  Malignant neoplasm of larynx
  •   C10 -  Malignant neoplasm of oropharynx
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Patient with squamous cell cancer of the head and neck with indication for surgical resection.
    Tumor- and adjacent non-malignant material, as well as peripheral blood are obtained for laboratory analyses (HLA ligandome, exome, transcriptome, evalutation of antigen-specific T cells in ELISpot and intracellular cytokine staining).
  •   Control group for the evaluation of antigen-specific T cells only: Patient with squamous cell carcinoma of the head and neck without indication for surgical intervention or small tumors.
    Cave: No tumor and non-malignant tissue is obtained.
end of 1:N-Block interventions
start of 1:1-Block design


  •   Non-interventional
  •   Other
  •   Other
  •   Open (masking not used)
  •   [---]*
  •   Other
  •   Basic research/physiological study
  •   Parallel
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Identification of HLA-presented tumor-associated and/or tumor-specific ligands (HLA-ligandome)

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Evaluation of the immunological relevance of the identified ligands
- Evaluation of metabolic pathways

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   Actual
  •   2018/01/15
  •   60
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Squamous cell carcinoma of the head and neck with indication for surgical resection

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Relevant comorbidities
- no indication for surgery
- insufficient amount of tumor material

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Europäische Union
    • Brüssel
    • Belgium
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.